Dr Kevin Doyle Appointed Head of Chemistry at Domainex
Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. Credit: Domainex Ltd
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. His appointment strengthens the expanding team of international scientists at its research facilities on Chesterford Research Park, based in Cambridge, UK, which has grown by more than 50% in the past 18 months.
‘I am delighted to join the team at Domainex,’ said Dr Doyle. ‘Domainex is clearly a rapidly-growing CRO and has been ‘one to watch’ for some time now. The opportunity to be a part of it, and to help shape the future of its medicinal chemistry was one that I could not miss. I am looking forward to working alongside the talented scientists there and to meeting and supporting the impressive list of clients from all around the world.'
Kevin Doyle is a medicinal chemist with more than 20 years’ experience in the pharmaceutical industry. He joins Domainex from Charles River Laboratories where he led numerous integrated drug discovery projects with international pharmaceutical and biotech companies, as well as with patient foundations. In previous roles, he worked at BASF and OSI Pharmaceuticals
‘We are delighted to welcome Kevin to Domainex,’ commented Dr Tom Mander, COO of the company. ‘His wealth of experience within the contract drug discovery research environment will be invaluable in helping Domainex to strengthen our integrated drug discovery platform further. Kevin will play a strategic role in attracting more pharmaceutical and biotechnology companies to Domainex, developing innovative new services and helping to extend our reputation for delivering innovative new medicinal therapies for our clients.’
This article has been republished from materials provided by Domainex. Note: material may have been edited for length and content. For further information, please contact the cited source.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.